152 related articles for article (PubMed ID: 25885468)
1. A new relative tumor sizing method in epi-metaphyseal osteosarcoma.
Kim SH; Shin KH; Park EH; Cho YJ; Park BK; Suh JS; Yang WI
BMC Cancer; 2015 Apr; 15():284. PubMed ID: 25885468
[TBL] [Abstract][Full Text] [Related]
2. Relative tumor burden predicts metastasis-free survival in pediatric osteosarcoma.
Lee JA; Kim MS; Kim DH; Lim JS; Yoo JY; Koh JS; Lee SY; Jeon DG; Park KD
Pediatr Blood Cancer; 2008 Feb; 50(2):195-200. PubMed ID: 18061933
[TBL] [Abstract][Full Text] [Related]
3. [The prognostic significance of tumor volume in osteosarcoma with neoadjuvant chemotherapy].
Rehan N; Bieling P; Winkler P; Helmke K; Maas R; Baldini N; Heise U; Fuchs N; Winkler K
Klin Padiatr; 1993; 205(4):200-9. PubMed ID: 8377444
[TBL] [Abstract][Full Text] [Related]
4. Effect of increases in tumor volume after neoadjuvant chemotherapy on the outcome of stage II osteosarcoma regardless of histological response.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jung ST; Jeon DG
J Orthop Sci; 2009 May; 14(3):292-7. PubMed ID: 19499296
[TBL] [Abstract][Full Text] [Related]
5. Tumor size and prognosis in aggressively treated osteosarcoma.
Bieling P; Rehan N; Winkler P; Helmke K; Maas R; Fuchs N; Bielack S; Heise U; Jurgens H; Treuner J; Romanowski R; Exner U; Kotz R; Winkler K
J Clin Oncol; 1996 Mar; 14(3):848-58. PubMed ID: 8622033
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
[TBL] [Abstract][Full Text] [Related]
7. Location of residual viable tumor cells after neoadjuvant chemotherapy: A new concept with high prognostic performance in osteosarcoma.
Kim SH; Shin KH; Moon SH; Kong Y; Suh JS; Yang WI
J Surg Oncol; 2017 May; 115(6):752-759. PubMed ID: 28403564
[TBL] [Abstract][Full Text] [Related]
8. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
9. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
Ann Surg Oncol; 2008 Mar; 15(3):906-14. PubMed ID: 18163171
[TBL] [Abstract][Full Text] [Related]
11. [Survival analysis and the effects of prognostic factors in patients treated for osteosarcoma].
Ozger H; Eralp L; Atalar AC; Toker B; Ayan I; Kebudi R; Bağbek S; Başaran M; Ağaoğlu F; Dizdar Y; Bilgiç B
Acta Orthop Traumatol Turc; 2007; 41(3):211-9. PubMed ID: 17876121
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
[TBL] [Abstract][Full Text] [Related]
13. Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients.
Bacci G; Longhi A; Cesari M; Versari M; Bertoni F
Cancer; 2006 Jun; 106(12):2701-6. PubMed ID: 16691623
[TBL] [Abstract][Full Text] [Related]
14. [Osteosarcoma lung metastases. Survival after chemotherapy and surgery].
Farfalli GL; Albergo JI; Lobos PA; Smith DE; Streitenberger PD; Pallotta Rodríguez MG; Aponte-Tinao LA
Medicina (B Aires); 2015; 75(2):87-90. PubMed ID: 25919869
[TBL] [Abstract][Full Text] [Related]
15. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.
Iwamoto Y; Tanaka K; Isu K; Kawai A; Tatezaki S; Ishii T; Kushida K; Beppu Y; Usui M; Tateishi A; Furuse K; Minamizaki T; Kawaguchi N; Yamawaki S
J Orthop Sci; 2009 Jul; 14(4):397-404. PubMed ID: 19662473
[TBL] [Abstract][Full Text] [Related]
16. Proximal tumor location and fluid-fluid levels on MRI predict resistance to chemotherapy in stage IIB osteosarcoma.
Jeon DG; Song WS; Cho WH; Kong CB; Cho SH
Clin Orthop Relat Res; 2014 Jun; 472(6):1911-20. PubMed ID: 24574120
[TBL] [Abstract][Full Text] [Related]
17. Post operative infection and increased survival in osteosarcoma patients: are they associated?
Jeys LM; Grimer RJ; Carter SR; Tillman RM; Abudu A
Ann Surg Oncol; 2007 Oct; 14(10):2887-95. PubMed ID: 17653803
[TBL] [Abstract][Full Text] [Related]
18. Examination of the cutoff value of postchemotherapy increase in tumor volume as a predictor of subsequent oncologic events in stage IIB osteosarcoma.
Jeon DG; Kong CB; Cho WH; Song WS; Cho SH; Choi SW; Lee SY
J Surg Oncol; 2014 Mar; 109(3):275-9. PubMed ID: 24243222
[TBL] [Abstract][Full Text] [Related]
19. Survival and prognostic factors at time of diagnosis in high-grade appendicular osteosarcoma: a 21 year single institution evaluation from east Denmark.
Colding-Rasmussen T; Thorn AP; Horstmann P; Rechnitzer C; Hjalgrim LL; Krarup-Hansen A; Petersen MM
Acta Oncol; 2018 Mar; 57(3):420-425. PubMed ID: 28741397
[TBL] [Abstract][Full Text] [Related]
20. Caffeine-potentiated chemotherapy for metastatic osteosarcoma.
Kimura H; Tsuchiya H; Shirai T; Nishida H; Hayashi K; Takeuchi A; Ohnari I; Tomita K
J Orthop Sci; 2009 Sep; 14(5):556-65. PubMed ID: 19802667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
